Challenging beliefs of testosterone therapy and prostate cancer - PubMed (original) (raw)

Challenging beliefs of testosterone therapy and prostate cancer

Linda My Huynh et al. Nat Rev Urol. 2019 Dec.

No abstract available

PubMed Disclaimer

References

    1. Stavropouls, K. et al. Testosterone replacement therapy and cardiovascular risk - a closer look at additional parameters. JAMA Intern Med. 117, 1393 (2017). -DOI
    1. Lopez, D. S. et al. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database. Clin. Endocrinol. https://doi.org/10.1111/cen.14093 (2019). -DOI
    1. Loeb, S. et al. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J. Clin. Oncol. 35, 1430–1436 (2017). -DOI
    1. Isbarn, H. et al. Testosterone and prostate cancer: revisiting old paradigms. Eur. Urol. 56, 48–56 (2009). -DOI
    1. Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate vancer. N. Engl. J. Med. 380, 1235–1246 (2019). -DOI

Publication types

MeSH terms

Substances

LinkOut - more resources